
### [MONDO:0018132](http://purl.obolibrary.org/obo/MONDO_0018132)
**Label:** congenital muscular alpha-dystroglycanopathy with brain and eye anomalies

**Subclasses:** [MONDO:0014101](http://purl.obolibrary.org/obo/MONDO_0014101) (muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type a, 12), [MONDO:0013904](http://purl.obolibrary.org/obo/MONDO_0013904) (muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type a, 8), [MONDO:0014120](http://purl.obolibrary.org/obo/MONDO_0014120) (muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 13), [MONDO:0019523](http://purl.obolibrary.org/obo/MONDO_0019523) (Walker-Warburg syndrome), [MONDO:0014022](http://purl.obolibrary.org/obo/MONDO_0014022) (muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type a, 10), [MONDO:0014683](http://purl.obolibrary.org/obo/MONDO_0014683) (muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 9), [MONDO:0013835](http://purl.obolibrary.org/obo/MONDO_0013835) (muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type a, 7), [MONDO:0018280](http://purl.obolibrary.org/obo/MONDO_0018280) (muscle-eye-brain disease with bilateral multicystic leucodystrophy), 

**Corr. equiv. classes:** [OMIM:616538](http://purl.obolibrary.org/obo/OMIM_616538), [OMIM:614830](http://purl.obolibrary.org/obo/OMIM_614830), [OMIM:614643](http://purl.obolibrary.org/obo/OMIM_614643), [OMIM:615249](http://purl.obolibrary.org/obo/OMIM_615249), [Orphanet:899](http://www.orpha.net/ORDO/Orphanet_899), [OMIM:615041](http://purl.obolibrary.org/obo/OMIM_615041), [OMIM:615287](http://purl.obolibrary.org/obo/OMIM_615287), [Orphanet:370997](http://www.orpha.net/ORDO/Orphanet_370997), 

**Class expressions from DL-Learner:**

- [HP:0001290](http://purl.obolibrary.org/obo/HP_0001290) (Generalized hypotonia) and [HP:0002119](http://purl.obolibrary.org/obo/HP_0002119) (Ventriculomegaly) and [HP:0007260](http://purl.obolibrary.org/obo/HP_0007260) (Type II lissencephaly) 62.50%
- [HP:0001290](http://purl.obolibrary.org/obo/HP_0001290) (Generalized hypotonia) and [HP:0002119](http://purl.obolibrary.org/obo/HP_0002119) (Ventriculomegaly) and [HP:0007260](http://purl.obolibrary.org/obo/HP_0007260) (Type II lissencephaly) and [HP:0007973](http://purl.obolibrary.org/obo/HP_0007973) (Retinal dysplasia) 62.50%
- [HP:0007260](http://purl.obolibrary.org/obo/HP_0007260) (Type II lissencephaly) 62.26%
- [HP:0000478](http://purl.obolibrary.org/obo/HP_0000478) (Abnormality of the eye) and [HP:0007260](http://purl.obolibrary.org/obo/HP_0007260) (Type II lissencephaly) 62.26%
- [HP:0001274](http://purl.obolibrary.org/obo/HP_0001274) (Agenesis of corpus callosum) and [HP:0007260](http://purl.obolibrary.org/obo/HP_0007260) (Type II lissencephaly) 57.48%
- [HP:0001274](http://purl.obolibrary.org/obo/HP_0001274) (Agenesis of corpus callosum) and [HP:0007260](http://purl.obolibrary.org/obo/HP_0007260) (Type II lissencephaly) and [HP:0040081](http://purl.obolibrary.org/obo/HP_0040081) (Abnormal levels of creatine kinase in blood) 57.48%
- [HP:0001274](http://purl.obolibrary.org/obo/HP_0001274) (Agenesis of corpus callosum) and [HP:0007260](http://purl.obolibrary.org/obo/HP_0007260) (Type II lissencephaly) and [HP:0012759](http://purl.obolibrary.org/obo/HP_0012759) (Neurodevelopmental abnormality) 57.48%
- [HP:0001274](http://purl.obolibrary.org/obo/HP_0001274) (Agenesis of corpus callosum) and [HP:0007260](http://purl.obolibrary.org/obo/HP_0007260) (Type II lissencephaly) and [HP:0012638](http://purl.obolibrary.org/obo/HP_0012638) (Abnormality of nervous system physiology) 57.48%
- [HP:0001274](http://purl.obolibrary.org/obo/HP_0001274) (Agenesis of corpus callosum) and [HP:0007260](http://purl.obolibrary.org/obo/HP_0007260) (Type II lissencephaly) and [HP:0012374](http://purl.obolibrary.org/obo/HP_0012374) (Abnormality of the globe) 57.48%
- [HP:0001274](http://purl.obolibrary.org/obo/HP_0001274) (Agenesis of corpus callosum) and [HP:0007260](http://purl.obolibrary.org/obo/HP_0007260) (Type II lissencephaly) and [HP:0012373](http://purl.obolibrary.org/obo/HP_0012373) (Abnormal eye physiology) 57.48%
- [HP:0001274](http://purl.obolibrary.org/obo/HP_0001274) (Agenesis of corpus callosum) and [HP:0007260](http://purl.obolibrary.org/obo/HP_0007260) (Type II lissencephaly) and [HP:0012372](http://purl.obolibrary.org/obo/HP_0012372) (Abnormal eye morphology) 57.48%
- [HP:0001274](http://purl.obolibrary.org/obo/HP_0001274) (Agenesis of corpus callosum) and [HP:0007260](http://purl.obolibrary.org/obo/HP_0007260) (Type II lissencephaly) and [HP:0011842](http://purl.obolibrary.org/obo/HP_0011842) (Abnormality of skeletal morphology) 57.48%
- [HP:0001274](http://purl.obolibrary.org/obo/HP_0001274) (Agenesis of corpus callosum) and [HP:0007260](http://purl.obolibrary.org/obo/HP_0007260) (Type II lissencephaly) and [HP:0011805](http://purl.obolibrary.org/obo/HP_0011805) (Abnormality of muscle morphology) 57.48%
- [HP:0001274](http://purl.obolibrary.org/obo/HP_0001274) (Agenesis of corpus callosum) and [HP:0007260](http://purl.obolibrary.org/obo/HP_0007260) (Type II lissencephaly) and [HP:0011804](http://purl.obolibrary.org/obo/HP_0011804) (Abnormality of muscle physiology) 57.48%
- [HP:0001274](http://purl.obolibrary.org/obo/HP_0001274) (Agenesis of corpus callosum) and [HP:0007260](http://purl.obolibrary.org/obo/HP_0007260) (Type II lissencephaly) and [HP:0011283](http://purl.obolibrary.org/obo/HP_0011283) (Abnormality of the metencephalon) 57.48%


